SURMOUNT-REAL UK_I8F-MC-GPJF
Research type
Research Study
Full title
A Phase 4 Multicenter, Randomized, Open-Label, Interventional Study with Pragmatic Elements Investigating the Effectiveness of Tirzepatide Once Weekly Compared with Standard of Care in Adult Participants with Obesity and without Diabetes in a Real-World Setting (SURMOUNT-REAL UK)
IRAS ID
1012506
Contact name
Maryna Kvochka
Contact email
Sponsor organisation
Eli Lilly and Company
Research summary
Obesity is a chronic disease associated with many conditions including type 2 diabetes, cardiovascular disease, increased risk for some cancers and increased risk for premature death. Evidence suggests that weight loss provides a wide array of health benefits and may play a crucial role in reducing the course of several chronic diseases.
Tirzepatide is a long-acting medication that works by mimicking two natural hormones (GIP and GLP-1) in the body that help control blood sugar and appetite. Nonclinical studies suggest the addition of GIP may also help reduce how much you eat. Tirzepatide helps people lower their body weight, mostly by reducing body fat rather than muscle. It likely works by making you feel less hungry, so you eat fewer calories.
SURMOUNT_REAL UK is a low interventional, phase 4, open label study. Participants will be randomly assigned to receive either Tirzepatide with standard of care treatment or receive standard of care treatment alone. The trial is designed to further support evidence generated from previous tirzepatide trials. It will assess weight reduction and its potential to delay progression to diabetes when delivered in a real-world setting.
Approximately 3000 participants will take part in the in the study in the UK. The study will last approximately 5 years.REC name
Wales REC 5
REC reference
25/WA/0237
Date of REC Opinion
30 Sep 2025
REC opinion
Further Information Favourable Opinion